Our studies shed a light on the role of CAFs-derived HAPLN1 in the pathogenesis of gastric cancer, and should provide novel CAFs-based strategies for the prevention and treatment of gastric carcinoma. This evidence concerns the gene HAPLN1 and gastric carcinoma.